A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination With the ATR Inhibitor Tuvusertib (M1774)
This study is testing two new medications, peposertib and tuvusertib, combined together to fight advanced solid tumors. Researchers want to find the safest and most effective dose to help stop cancer cells from growing.
Adults 18 and older with advanced solid tumors that have spread and no longer respond to standard treatments may be eligible. Participants must also have specific genetic markers in their tumors and a life expectancy of more than three months.
Participants will take the study medications and undergo regular health checks, including blood tests, tissue samples, and imaging scans like X-rays and MRIs to monitor their progress.
The study is currently recruiting patients and takes place at medical centers in locations such as Bethesda, Maryland, and Boston, Massachusetts.
- 1Tests a combination of two investigational cancer drugs.
- 2Aims to find the safest dose for patients with advanced solid tumors.
- 3Involves regular check-ups, scans, and lab tests to monitor your health.
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.